Lotus Pharmaceutical Revenue vs. Price To Book
| 1795 Stock | TWD 266.00 6.50 2.39% |
For Lotus Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lotus Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lotus Pharmaceutical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lotus Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lotus Pharmaceutical Co over time as well as its relative position and ranking within its peers.
Lotus |
Lotus Pharmaceutical Price To Book vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lotus Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Lotus Pharmaceutical value to that of its competitors to determine the firm's financial worth. Lotus Pharmaceutical Co is the top company in revenue category among its peers. It also is number one stock in price to book category among its peers . The ratio of Revenue to Price To Book for Lotus Pharmaceutical Co is about 2,544,647,649 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lotus Pharmaceutical's earnings, one of the primary drivers of an investment's value.Lotus Revenue vs. Competition
Lotus Pharmaceutical Co is the top company in revenue category among its peers. Market size based on revenue of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 212.62 Billion. Lotus Pharmaceutical holds roughly 12.65 Billion in revenue claiming about 6% of equities under Drug Manufacturers—Specialty & Generic industry.
Lotus Price To Book vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Lotus Pharmaceutical |
| = | 12.65 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Lotus Pharmaceutical |
| = | 4.97 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Lotus Price To Book Comparison
Lotus Pharmaceutical is currently under evaluation in price to book category among its peers.
Lotus Pharmaceutical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lotus Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lotus Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Lotus Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Lotus Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Lotus Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells medicines in Taiwan, Korea, the United States, and internationally. Lotus Pharmaceutical Co., Ltd. is a subsidiary of Alvogen Emerging Markets Holdings Limited. LOTUS PHARMACEUTICAL operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.
Lotus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lotus Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lotus Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lotus Pharmaceutical's important profitability drivers and their relationship over time.
Use Lotus Pharmaceutical in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lotus Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lotus Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Lotus Pharmaceutical Pair Trading
Lotus Pharmaceutical Co Pair Trading Analysis
The ability to find closely correlated positions to Lotus Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lotus Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lotus Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lotus Pharmaceutical Co to buy it.
The correlation of Lotus Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lotus Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lotus Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lotus Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lotus Pharmaceutical position
In addition to having Lotus Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Lotus Stock Analysis
When running Lotus Pharmaceutical's price analysis, check to measure Lotus Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceutical is operating at the current time. Most of Lotus Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceutical's price. Additionally, you may evaluate how the addition of Lotus Pharmaceutical to your portfolios can decrease your overall portfolio volatility.